TISSUE-BASED GENE EXPRESSION FOR PROGNOSIS OF PROSTATE CANCER LOCAL STAGE
https://doi.org/10.21886/2308-6424-2015-0-3-34-41
Abstract
The aim of our study was the evaluation of the prognostic role of 42 genes, which were shown to be relates to prostate cancer aggressiveness in previous studies. We have included 28 patients in the study, 19 with localized prostate cancer according to final pathology after radical prostatectomy (pT2a-2c) and 9 patients with locally advanced prostate cancer (pT3a-b). Analysis of the gene expression (PCR) revealed 6 genes with differential expression in tumor tissues of patients from 2 aforementioned groups: GOLM1, GBX2, XPO6, SSTR1, TOP2A and CDCA5. We have created a prognostic model of the pT-stage based on the expression of these 6 genes, which proved to be accurate in 75% of the included cases.
About the Authors
Yuri Tolkach
Hannover Medical School, Clinic for Urology and Urologic Oncology
Germany
Germany
Markus Kuczyk
Hannover Medical School, Clinic for Urology and Urologic Oncology
Germany
Germany
Axel Merseburger
Hannover Medical School, Clinic for Urology and Urologic Oncology
Germany
Germany
Jürgen Serth
Hannover Medical School, Clinic for Urology and Urologic Oncology
Germany
Germany
Thomas Herrmann
Hannover Medical School, Clinic for Urology and Urologic Oncology
Germany
Germany
Florian Imkamp
Hannover Medical School, Clinic for Urology and Urologic Oncology
Germany
Germany
References
1. Eifler, JB. Anupdated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 / J.B. Eifler, Z. Feng,B.M. Lin, M.T. Partin, et al. //BJU Int. – 2013, Vol.111. – P. 22-29.
2. Fraser, M. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer / M. Fraser, A. Berlin, R.G. Bristow, T. van der Kwast //Urol Oncol. – 2015, Vol. 33. – P. 85-94
3. Tomlins, SA. Integrative molecular concept modeling of prostate cancer progression / S.A. Tomlins, R. Mehra, D.R. Rhodes et al. // Nat Genet. – 2007, Vol. 39. – P. 41-51.
4. Barbieri CE. The mutational landscape of prostate cancer / C.E. Barbieri, C.H. Bangma, A. Bjartell, J.W. Catto // Eur Urol. – 2013, Vol. 64. – P. 567-576.
5. Bismar TA. Defining aggressive prostate cancer using a 12-gene model / T.A. Bismar, F. Demichelis, A. Riva et al. //Neoplasia. – 2006, Vol. 8. – P. 59-68.
6. Glinsky GV. Gene expression profiling predicts clinical outcome of prostate cancer / G.V. Glinsky, A.B. Glinskii, A.J. Stephenson, R.M. Hoffman, et al. //J Clin Invest. – 2004, Vol.113. –P. 913-923.
7. Kosari F. Identification of prognostic biomarkers for prostate cancer / F. Kosari, J.M.A. Munz, C.D. Savci-Heijink et al. //Clin Cancer Res. – 2008, Vol.14. – P. 1734-1743.
8. May F. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy / F. May, R. Hartung, J. Breul //BJU Int. – 2001, Vol. 88. – P. 702-707.
9. Van der Kwast TH. Prognostic prostate tissue biomarkers of potential clinical use / T.H. Van der Kwast //Virchows Arch. –2014, Vol.464. – P. 293-300.
Review
For citations:
Tolkach Yu., Kuczyk M., Merseburger A., Serth J., Herrmann T., Imkamp F. TISSUE-BASED GENE EXPRESSION FOR PROGNOSIS OF PROSTATE CANCER LOCAL STAGE. Urology Herald. 2015;(3):34-41. (In Russ.) https://doi.org/10.21886/2308-6424-2015-0-3-34-41
Views:
1293
Email this article 
